News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Artimplant Interim Report January - March 2010
May 4, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)--Regulatory News: Artimplant (STO:ARTIB): Net revenue amounted to SEK 4.8 million (4.8)*]
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Policy
Biopharma Could Provide a Haven for Investment as Middle East Conflict Roils Global Markets
March 20, 2026
·
2 min read
·
Annalee Armstrong
Manufacturing
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy
March 19, 2026
·
2 min read
·
Nick Paul Taylor
Layoffs
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail
March 19, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One
March 19, 2026
·
2 min read
·
Tristan Manalac
